Clinical Vignette
Patient: "Mr. Y," 28-year-old graduate student, presenting with escalating anxiety, panic-like episodes, and insomnia over the past 6 weeks.
Chief Concern: "I've been incredibly anxious for weeks. I can't sleep, my heart races randomly, I'm jittery all day, and I had 3 episodes where I thought I was going to die. This started out of nowhere."
History of Present Illness: Mr. Y reports the onset of severe anxiety symptoms 6 weeks ago. He describes persistent jitteriness, restlessness, racing heartbeat, difficulty concentrating on his thesis, insomnia (sleeps 3-4 hours nightly), and 3 episodes of acute panic (sudden onset palpitations, shortness of breath, fear of dying, lasting 15-20 minutes). He denies any psychosocial stressor. A careful substance history reveals: (1) He increased his coffee consumption from 2 cups to 6-8 cups daily (approximately 600-800mg caffeine) 7 weeks ago as thesis deadlines approached. (2) He began using daily cannabis edibles 5 weeks ago 'to relax' after the anxiety started. (3) His primary care physician prescribed albuterol inhaler 6 weeks ago for new-onset exercise-induced bronchospasm, which he uses 1-2 times daily. (4) He uses no other substances. No prior psychiatric history. No family history of anxiety disorders. He was described as 'laid-back' by friends throughout college.
Medical History: Exercise-induced bronchospasm (diagnosed 6 weeks ago). Albuterol inhaler prescribed.
Mental Status Exam: Restless, fidgety. Speech slightly rapid. Mood 'anxious.' Affect tense. Fine tremor in hands. Heart rate 98 (resting). Thought content: worry about thesis deadlines and physical symptoms. No psychotic symptoms. No depressive symptoms. Insight developing.
Step 1: Substance/Medication-Induced Anxiety DSM-5-TR Criteria
Criterion A: Panic attacks or anxiety is predominant in the clinical picture.
Persistent anxiety with 3 discrete panic episodes. Anxiety is the predominant clinical feature. MET.
Criterion B: Evidence that symptoms developed during or soon after substance intoxication or withdrawal, or after exposure to a medication, AND the substance/medication is capable of producing the symptoms.
Three potential substance/medication contributors identified, all temporally correlated with symptom onset: (1) massive caffeine increase (7 weeks ago), (2) cannabis initiation (5 weeks ago), (3) albuterol initiation (6 weeks ago). All three are known anxiogenic agents. MET — three contributing substances identified.
Criterion C: Not better explained by an independent anxiety disorder.
No prior anxiety history. No family history of anxiety. Premorbid personality described as 'laid-back.' Temporal onset precisely corresponds to substance changes. If symptoms were from an independent GAD, they would be expected to predate the substance changes. MET — temporal pattern strongly favors substance-induced etiology.
Step 2: Identifying Multiple Anxiogenic Contributors
| Substance | Mechanism | Onset Correlation | Contribution Assessment |
|---|---|---|---|
| Caffeine (600-800mg/day) | Adenosine receptor antagonism → sympathetic activation, sleep disruption, jitteriness, panic threshold lowering | Increased 7 weeks ago (1 week before symptoms) | PRIMARY contributor: dose exceeds anxiogenic threshold; onset precedes symptoms |
| Albuterol inhaler | Beta-2 agonist → tachycardia, tremor, restlessness, CNS stimulation | Started 6 weeks ago (concurrent with symptom onset) | SIGNIFICANT contributor: beta-agonist side effects mimic panic symptoms |
| Cannabis edibles | THC can paradoxically increase anxiety, particularly in anxiety-prone states; acute cannabis can trigger panic | Started 5 weeks ago (1 week after symptoms began) | COMPOUNDING factor: cannabis maintaining/worsening pre-existing anxiety rather than initiating it |
Multi-Substance Attribution
This presentation involves three converging anxiogenic factors. The caffeine escalation is the most likely initiator (onset 1 week before symptoms). Albuterol contributes tachycardia and tremor that mimic and reinforce panic symptoms. Cannabis, paradoxically, compounds the anxiety rather than relieving it.
Diagnostic Formulation
Diagnostic Conclusion
Substance/Medication-Induced Anxiety Disorder, with Panic Attacks (Multiple Substances: Caffeine F15.180, Cannabis F12.180; Medication: Albuterol): DSM-5-TR criteria met. Three anxiogenic substances/medications temporally correlated with onset. No prior anxiety history. Premorbid low-anxiety personality. Treatment: (1) Taper caffeine to ≤200mg/day (2 cups). (2) Discontinue cannabis. (3) Consult with PCP re: albuterol alternatives (ipratropium, inhaled corticosteroid). (4) Reassess after 4 weeks of substance modification before diagnosing or treating a primary anxiety disorder.
Teaching Points
- Caffeine's anxiogenic dose threshold is individually variable but consistently documented above 400mg/day. At 600-800mg/day, caffeine reliably produces anxiety symptoms in most individuals: restlessness, insomnia, tachycardia, and lowered panic threshold.
- Beta-agonist inhalers (albuterol, levalbuterol) produce tachycardia, tremor, and restlessness as expected pharmacological effects. In anxious patients, these side effects are often catastrophically misinterpreted as panic symptoms, creating a self-reinforcing cycle.
- Cannabis has bidirectional effects on anxiety: low doses may reduce anxiety, but higher doses or chronic use (particularly THC-dominant products) can increase anxiety, paranoia, and panic. Cannabis edibles are particularly problematic because delayed onset leads to dose stacking.
- The DSM-5-TR diagnostic algorithm requires EXHAUSTING substance-induced etiologies before assigning a primary anxiety disorder. A 4-week washout period after substance modification is standard before concluding that symptoms represent an independent anxiety disorder.
- Mr. Y's case illustrates the 'perfect storm' of converging anxiogenic factors. Each substance individually might not have produced clinical anxiety, but their combined effect exceeded his threshold. Treatment requires addressing ALL contributing factors, not just one.